IRLAB’s Year-end report January 1 – December 31, 2020
Significant events during the fourth quarter (October 1 – December 31, 2020) · In October, the US FDA accepted mesdopetam as an investigational new drug (IND). The acceptance allows IRLAB to include patients in the US in the clinical Phase IIb/III study with mesdopetam in levodopa-induced dyskinesias in Parkinson’s (PD-LIDs). · Early November, patient recruitment started in the US to the Phase IIb/III study with mesdopetam in PD-LIDs and the first patients started treatment before end of year. · In the beginning of December, the World Intellectual Property Organization (WIPO)